Company Focus
Sun Pharmaceuticals
Latest Sun Pharmaceuticals News
Biotechnology
India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA. 6 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Sun Pharmaceuticals
Pharmaceutical
Bensheim-based medical cannabis specialist Avextra has announced a strategic partnership with fellow German firm SynQube. 20 June 2024
Biotechnology
Chicago, USA-based biopharma giant AbbVie has picked up a new nod for Skyrizi (risankizumab-rzaa), for adults with moderately to severely active ulcerative colitis. 19 June 2024
Pharmaceutical
CNS disorder specialist Intra-Cellular Therapies has announced positive to-pline results from Study 502, evaluating its depression candidate lumateperone. 19 June 2024
Biotechnology
Third Rock incubated clinical-stage biotech Marea Therapeutics launched yesterday with $190 million in combined Series A and B financings. 19 June 2024
Pharmaceutical
The Swiss company Swixx BioPharma has stopped the supplies of Humalog insulin (insulin lispro) to Russia due to the decision of its manufacturer, the American pharma major Eli Lilly, The Pharma Letter’s local correspondent reports. 19 June 2024
Biotechnology
Boston, USA-based biotech start-up Ascidian Therapeutics yesterday announced a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases, adding to the Swiss pharma giant’s plethora of RNA alliances. 19 June 2024
Biotechnology
US biotech Arvinas has promoted Ian Taylor to president of R&D. Angela Cacace will take over from Dr Taylor in his current role of chief scientific officer. 18 June 2024
Pharmaceutical
Marinus Pharmaceuticals has announced topline results showing partial success in the Phase III RAISE trial. 18 June 2024
Pharmaceutical
The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting. 18 June 2024
Biotechnology
US liver disease focused biotech Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares leap 15.4% to $29.90 by close of trading on Monday, as it reported interim results from two Phase IIb studies evaluating volixibat. 18 June 2024
Latest In Brief for Sun Pharmaceuticals
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Relevant Ones To Watch News
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
12 November 2024
30 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze